Baseline characteristics | Subjects with incident T2DM | Subjects without incident T2DM |
---|---|---|
n (%) | n (%) | |
All patients (n = 2,016,094) | 130,395 (6.47) | 1,885,699 (93.53) |
Gender | Â | Â |
Male | 70,972 (54.43) | 995,813 (52.81) |
Female | 59,423 (45.57) | 889,886 (47.19) |
Age mean (sd), yrs | 63.44 (10.54) | 62.19 (11.24) |
30-39 | 1,697 (1.30) | 43,108 (2.29) |
40-49 | 11,324 (8.68) | 209,938 (11.13) |
50-59 | 33,703 (25.85) | 522,025 (27.68) |
60-69 | 43,636 (33.46) | 592,927 (31.44) |
70-79 | 32,174 (24.67) | 389,694 (20.67) |
80-85 | 7,861 (6.03) | 128,007 (6.79) |
BMI, kg/m 2 | Â | Â |
 <20 | 2,461 (1.89) | 74,258 (3.94) |
 20-25 | 20,947 (16.06) | 544,004 (28.85) |
 >25 | 102,001 (78.22) | 1,020,270 (54.11) |
 Unknown | 4,986 (3.82) | 247,167 (13.11) |
Smoking status | Â | Â |
Current smokers | 21,742 (16.67) | 335,261 (17.78) |
Former smoker | 59,403 (45.56) | 636,260 (33.74) |
Non-smoker/never | 48,775 (37.41) | 833,493 (44.20) |
Unknown status | 475 (0.36) | 80,685 (4.28) |
Alcohol use | Â | Â |
Current (unknown amount) | 5,044 (3.87) | 59,727 (3.17) |
Rare drinker (<2u/d) | 21,939 (16.83) | 271,032 (14.37) |
Moderate drinker (3-6u/d) | 64,639 (49.57) | 916,543 (48.60) |
Excessive drinker (>6u/d) | 40,912 (9.49) | 135,790 (8.57) |
Past use | 4,200 (3.22) | 44,267 (2.35) |
Non-drinker | 17,844 (13.68) | 197,361 (10.47) |
Unknown status | 5,809 (4.45) | 230,987 (12.25) |
Family history of: | Â | Â |
Diabetes | 6,607 (5.07) | 67,269 (3.57) |
Cardiovascular disease | 29,012 (22.25) | 391,498 (20.76) |
Diagnosis of: | Â | Â |
Hyperlipidaemia | 6,372 (4.89) | 53,045 (2.81) |
Atherosclerosis | 373 (0.29) | 3.466 (0.18) |
Hypertension | 50,529 (38.75) | 478,788 (25.39) |
Heart failure | 3,235 (2.48) | 27,373 (1.45) |
Cardiovascular disease | 20,852 (15.99) | 179,553 (9.52) |
Atrial fibrillation | 5,117 (3.92) | 48,795 (2.59) |
Hepatic disease (within 6Â months) | 787 (0.60) | 6,757 (0.36) |
Kidney disease (within 6Â months) | 2,671 (2.05) | 38,494 (2.04) |
Abnormal glucose level | 3,780 (2.90) | 14,053 (0.75) |
Osteoporosis | 3,099 (2.38) | 55,210 (2.93) |
Cancer | 12,916 (9.91) | 189,677 (10.06) |
Thyroid disease | 10,747 (8.24) | 129,671 (6.88) |
Prior use of: | Â | Â |
Antipsychotics (within 6Â months) | 114 ( 0.09) | 1,455 (0.08) |
Antidepressants (within 6Â months) | 1,503 (1.15) | 19,868 (1.05) |
Cardiovascular drugs | 53,096 (40.72) | 680,014 (36.06) |
Nonstatin lipid lowerers (within 3Â months) | 189 (0.14) | 1,041 (0.06) |
Systemic glucocorticoids (within 6Â months) | 1,496 (1.15) | 18,475 (0.98) |
Oestrogens/HRT (within 1Â year) | 706 (0.54) | 8,781 (0.47) |
Bisphosphonates | 699 (0.54) | 11,765 (0.62) |
CYP450 3A4 inhibitor | 1,709 (1.31) | 18,616 (0.99) |
Annual consultation rate, mean (SD) | 22.16 (19.33) | 17.66 (18.04) |
Annual prescription rate, mean (SD) | 19.42 (30.12) | 11.57 (24.27) |